Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 197

1.

Personalized laboratory medicine: a patient-centered future approach.

Prodan Žitnik I, Černe D, Mancini I, Simi L, Pazzagli M, Di Resta C, Podgornik H, Repič Lampret B, Trebušak Podkrajšek K, Sipeky C, van Schaik R, Brandslund I, Vermeersch P, Schwab M, Marc J; behalf of EFLM/ESPT working group of Personalised Laboratory Medicine on.

Clin Chem Lab Med. 2018 Nov 27;56(12):1981-1991. doi: 10.1515/cclm-2018-0181. Review.

PMID:
29990304
2.

New insights in the clinical and translational relevance of miR483-5p in adrenocortical cancer.

Salvianti F, Canu L, Poli G, Armignacco R, Scatena C, Cantini G, Di Franco A, Gelmini S, Ercolino T, Pazzagli M, Nesi G, Mannelli M, Pinzani P, Luconi M.

Oncotarget. 2017 Jul 10;8(39):65525-65533. doi: 10.18632/oncotarget.19118. eCollection 2017 Sep 12.

3.

Circulating tumor cells and microemboli can differentiate malignant and benign pulmonary lesions.

Mascalchi M, Maddau C, Sali L, Bertelli E, Salvianti F, Zuccherelli S, Matucci M, Borgheresi A, Raspanti C, Lanzetta M, Falchini M, Mazza E, Vella A, Luconi M, Pinzani P, Pazzagli M.

J Cancer. 2017 Jul 15;8(12):2223-2230. doi: 10.7150/jca.18418. eCollection 2017.

4.

Powerful qPCR assays for the early detection of latent invaders: interdisciplinary approaches in clinical cancer research and plant pathology.

Luchi N, Capretti P, Pazzagli M, Pinzani P.

Appl Microbiol Biotechnol. 2016 Jun;100(12):5189-204. doi: 10.1007/s00253-016-7541-5. Epub 2016 Apr 25. Review.

PMID:
27112348
5.

Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing.

Salvianti F, Rotunno G, Galardi F, De Luca F, Pestrin M, Vannucchi AM, Di Leo A, Pazzagli M, Pinzani P.

Biomol Detect Quantif. 2015 Sep 12;5:23-9. doi: 10.1016/j.bdq.2015.07.002. eCollection 2015 Sep.

6.

Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer.

De Luca F, Rotunno G, Salvianti F, Galardi F, Pestrin M, Gabellini S, Simi L, Mancini I, Vannucchi AM, Pazzagli M, Di Leo A, Pinzani P.

Oncotarget. 2016 May 3;7(18):26107-19. doi: 10.18632/oncotarget.8431.

7.

Urinary carbonic anhydrase IX splicing messenger RNA variants in urogenital cancers.

Malentacchi F, Vinci S, Melina AD, Kuncova J, Villari D, Nesi G, Selli C, Orlando C, Pazzagli M, Pinzani P.

Urol Oncol. 2016 Jul;34(7):292.e9-292.e16. doi: 10.1016/j.urolonc.2016.02.017. Epub 2016 Mar 19.

PMID:
27005925
8.

Data and performances evaluation of the SPIDIA-DNA Pan-European External Quality Assessment: 2nd SPIDIA-DNA laboratory report.

Malentacchi F, Pizzamiglio S, Ibrahim-Gawel H, Pazzagli M, Verderio P, Ciniselli CM, Wyrich R, Gelmini S.

Data Brief. 2016 Feb 6;6:980-4. doi: 10.1016/j.dib.2016.01.062. eCollection 2016 Mar.

9.

Effects of Transport and Storage Conditions on Gene Expression in Blood Samples.

Malentacchi F, Pizzamiglio S, Wyrich R, Verderio P, Ciniselli C, Pazzagli M, Gelmini S.

Biopreserv Biobank. 2016 Apr;14(2):122-8. doi: 10.1089/bio.2015.0037. Epub 2016 Feb 17.

PMID:
26886447
10.

Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma.

Salvianti F, Orlando C, Massi D, De Giorgi V, Grazzini M, Pazzagli M, Pinzani P.

Front Mol Biosci. 2016 Jan 8;2:76. doi: 10.3389/fmolb.2015.00076. eCollection 2015.

11.

Second SPIDIA-DNA External Quality Assessment (EQA): Influence of pre-analytical phase of blood samples on genomic DNA quality.

Malentacchi F, Pizzamiglio S, Ibrahim-Gawel H, Pazzagli M, Verderio P, Ciniselli CM, Wyrich R, Gelmini S.

Clin Chim Acta. 2016 Feb 15;454:10-4. doi: 10.1016/j.cca.2015.12.032. Epub 2015 Dec 23.

PMID:
26721315
12.

Single circulating tumor cell sequencing as an advanced tool in cancer management.

Salvianti F, Pazzagli M, Pinzani P.

Expert Rev Mol Diagn. 2016;16(1):51-63. doi: 10.1586/14737159.2016.1116942. Epub 2015 Nov 26. Review.

PMID:
26560087
13.

Prevalence and number of circulating tumour cells and microemboli at diagnosis of advanced NSCLC.

Mascalchi M, Falchini M, Maddau C, Salvianti F, Nistri M, Bertelli E, Sali L, Zuccherelli S, Vella A, Matucci M, Voltolini L, Pegna AL, Luconi M, Pinzani P, Pazzagli M.

J Cancer Res Clin Oncol. 2016 Jan;142(1):195-200. doi: 10.1007/s00432-015-2021-3. Epub 2015 Jul 26.

PMID:
26210156
14.

Prospective evaluation of RASSF1A cell-free DNA as a biomarker of pre-eclampsia.

Salvianti F, Inversetti A, Smid M, Valsecchi L, Candiani M, Pazzagli M, Cremonesi L, Ferrari M, Pinzani P, Galbiati S.

Placenta. 2015 Sep;36(9):996-1001. doi: 10.1016/j.placenta.2015.07.003. Epub 2015 Jul 7.

PMID:
26183647
15.

Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.

Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F.

World J Gastroenterol. 2015 Jun 21;21(23):7281-8. doi: 10.3748/wjg.v21.i23.7281.

16.

Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe.

Malentacchi F, Mancini I, Brandslund I, Vermeersch P, Schwab M, Marc J, van Schaik RH, Siest G, Theodorsson E, Pazzagli M, Di Resta C; European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) – European Society of Pharmacogenomics and Personalised Therapy (ESPT) Joint Working Group on Personalized Laboratory Medicine (WG-PLM).

Drug Metab Pers Ther. 2015 Jun;30(2):121-8. doi: 10.1515/dmdi-2015-0012.

17.

Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe.

Malentacchi F, Mancini I, Brandslund I, Vermeersch P, Schwab M, Marc J, van Schaik RH, Siest G, Theodorsson E, Pazzagli M, Di Resta C; European Federation of Clinical Chemistry and Laboratory Medicine (EFLM); European Society of Pharmacogenomics and Personalised Therapy (ESPT) Joint Working Group on Personalized Laboratory Medicine (WG-PLM).

Clin Chem Lab Med. 2015 Jun;53(7):981-8.

18.

Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): the SPIDIA-DNAplas External Quality Assessment experience.

Malentacchi F, Pizzamiglio S, Verderio P, Pazzagli M, Orlando C, Ciniselli CM, Günther K, Gelmini S.

Clin Chem Lab Med. 2015 Nov;53(12):1935-42. doi: 10.1515/cclm-2014-1161.

PMID:
25883202
19.

Combining qualitative and quantitative imaging evaluation for the assessment of genomic DNA integrity: The SPIDIA experience.

Ciniselli CM, Pizzamiglio S, Malentacchi F, Gelmini S, Pazzagli M, Hartmann CC, Ibrahim-Gawel H, Verderio P.

Anal Biochem. 2015 Jun 15;479:60-2. doi: 10.1016/j.ab.2015.03.023. Epub 2015 Mar 27.

PMID:
25817220
20.

Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.

Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, Pazzagli M, Di Leo A, Pinzani P.

Mol Oncol. 2015 Apr;9(4):749-57. doi: 10.1016/j.molonc.2014.12.001. Epub 2014 Dec 9.

Supplemental Content

Loading ...
Support Center